Skip to content
Clinical Trials – home

Azienda USL Toscana Centro

Verified siteinfo

Italy Via Suor Niccolina Infermiera 20/22, 59100 Prato, Italy

  • 26 trials recruiting
  • Breast cancer · Hormone receptor positive HER2 negative breast cancer · Fallopian tube cancer
  • Adults and children

About Specializations

Azienda USL Toscana Centro in Prato, Italy specialises in clinical trials of conditions such as Breast cancer, Hormone receptor positive HER2 negative breast cancer, Fallopian tube cancer, Ovarian cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms Research at Azienda USL Toscana Centro

At Azienda USL Toscana Centro in Prato, the clinical trial program is focused on neoplasms, with studies exploring new ways to treat several difficult-to-manage cancers and rare tumors. The research includes work on improving treatment effectiveness, delaying disease progression, and testing promising therapies for both early-stage and advanced disease.

  • Endometrial cancer research is evaluating a new maintenance approach for advanced or recurrent disease to better control cancer growth.
  • Studies in colorectal cancer are assessing short-course preoperative targeted treatments for molecularly selected resectable tumors.
  • Trials in ovarian, fallopian tube, and primary peritoneal cancers are testing maintenance strategies for platinum-sensitive disease.
  • Breast cancer research covers both ER-positive/HER2-negative early breast cancer and HER2-low or HER2 IHC 0 metastatic breast cancer, with studies aimed at improving anti-tumor activity and treatment outcomes.
  • A rare tumor study is focused on tenosynovial giant cell tumor, evaluating whether a new therapy can reduce tumor activity.

Overall, the site’s oncology team is investigating therapies designed to improve response rates, extend progression-free survival, and support more effective care across a range of solid tumors.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Suor Niccolina Infermiera 20/2259100 PratoItaly
Recruiting now
26 trials
Conditions studied
57
Partner status
Verified site

More sites in PratoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

63 clinical trials

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin
  • Sponsor:Italian Sarcoma Group
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.